Development of α‐Tocopherol Loaded PLGA Nanoparticles and Its Evaluation as a Novel Immune Adjuvant

Abstract With the continuous development of preventive and therapeutic vaccines, traditional adjuvants cannot provide sufficient immune efficacy and it is of high necessity to develop safe and effective novel nanoparticle‐based vaccine adjuvants. α ‐Tocopherol (TOC) is commonly used in oil‐emulsion adjuvant systems as an immune enhancer, yet its bioavailability is limited by poor water solubility. This study aims to develop TOC‐loaded poly(lactic‐ co ‐glycolic acid) (PLGA) nanoparticles (TOC‐PLGA NPs) to explore the potential of TOC‐PLGA NPs as a novel nanoparticle‐immune adjuvant. TOC‐PLGA NPs are prepared by a nanoprecipitation method and their physicochemical properties are characterized. It is shown that TOC‐PLGA NPs are 110.8 nm, polydispersity index value of 0.042, and Zeta potential of −13.26 mV. The encapsulation efficiency and drug loading of NPs are 82.57% and 11.80%, respectively, and the cumulative release after 35 days of in vitro testing reaches 47%. Furthermore, TOC‐PLGA NPs demonstrate a superior promotion effect on RAW 264.7 cell proliferation compared to PLGA NPs, being well phagocytosed and also promoting antigen uptake by macrophages. TOC‐PLGA NPs can strongly upregulate the expression of co‐stimulatory surface molecules and the secretion of cytokines. In conclusion, TOC‐PLGA NPs can be a novel vaccine adjuvant with excellent biocompatibility and significant immune‐enhancing activity.